



SEQUENCE LISTING

<110> Max-Delbrueck-Centrum fuer Molekulare Medizin

<120> Tumor vaccines for mucl-positive carcinomas

<130> 0107-027

<140> Ser. No. 09/606,910

<141> 2000-06-29

<150> DE 197 58 400.4

<151> 1997-12-30

<150> PCT/DE98/03819

<151> 1998-12-30

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> human

7

<220>

<223> immunodominant region of MUC1

<400> 1

Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 2

<211> 8

<212> PRT

<213> mouse, IgG1

<220>

<223> A76-A/C7 epitope

<400> 2

Ala Pro Asp Thr Arg Pro Ala Pro

1

5

<210> 3

<211> 6

<212> PRT

<213> mouse, IgG1

<220>

<223> MFO6 epitope


RECEIVED  
JAN 30 2003  
TECH CENTER 1600/2900

<400> 3  
Asp Thr Arg Pro Ala Pro  
1 5

<210> 4  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: designed  
synthetical glycopeptide

<400> 4  
Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser  
1 5 10 15  
Thr Ala Pro Pro Ala  
20

 <210> 5  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: designed  
synthetical glycopeptide

<400> 5  
His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr  
1 5 10 15  
Ala Pro Pro Ala  
20

<210> 6  
<211> 7  
<212> PRT  
<213> human

<220>  
<221> DOMAIN  
<222> (1)..(7)  
<223> immunodominant motif of the epithelial mucin (  
MUC1)

<400> 6  
Pro Asp Thr Arg Pro Ala Pro  
1 5

---